Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

ConclusionNapabucasin was well-tolerated at doses up to 1440  mg/day in Japanese patients with advanced solid tumors; the PK profile was comparable to that reported previously.

Source: Cancer Chemotherapy and Pharmacology - March 30, 2020 Category: Cancer & Oncology Source Type: research